The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality - 27/09/18
, Julia R. DiBello c, Bonnie H. Li b, Stephen K. Van Den Eeden d, Sheila Weinmann e, Debra P. Ritzwoller f, Jill E. Abell g, Ralph D'Agostino h, Ronald K. Loo b, David S. Aaronson d, Ralph I. Horwitz i, Steven J. Jacobsen bAbstract |
Objective |
To compare the risk of mortality among men treated for benign prostatic hyperplasia (BPH) with 5 alpha-reductase inhibitors (5ARI) to those treated with alpha-blockers (AB) in community practice settings.
Methods |
We employed a retrospective matched cohort study in 4 regions of an integrated healthcare system. Men aged 50 years and older who initiated pharmaceutical treatment for BPH and/or lower urinary tract symptoms between 1992 and 2008 and had at least 3 consecutive prescriptions that were eligible and followed through 2010 (N = 174,895). Adjusted hazard ratios were used to estimate the risk of mortality due to all-causes associated with 5ARI use (with or without concomitant ABs) as compared to AB use.
Results |
In this large and diverse sample with 543,523 person-years of follow-up, 35,266 men died during the study period, 18.9% of the 5ARI users and 20.4% of the AB users. After adjustment for age, medication initiation year, race, region, prior AB history, Charlson score, and comorbidities, 5ARI use was not associated with an increased risk of mortality when compared to AB use (Adjusted hazard ratios: 0.64, 95% confidence interval: 0.62, 0.66).
Conclusion |
Among men receiving medications for BPH in community practice settings, 5ARI use was not associated with an increased risk of mortality when compared to AB use. These data provide reassurance about the safety of using 5ARIs in general practice to manage BPH and/or lower urinary tract symptoms.
Le texte complet de cet article est disponible en PDF.Keywords : Alpha-blockers, Benign prostatic hyperplasia, 5 Alpha-reductase inhibitors, Lower urinary tract symptoms, Mortality
Abbreviations : 5ARI, AB, BPH, LUTS, HR, KP, ED, OAB, PCPT
Plan
| ☆ | Conflict of Interest Disclosures:Drs. Wallner, Jacobsen, Abell, Van Den Eeden, D'Agsotino Jr., DiBello, Loo, and Horwitz report funding from GlaxoSmithKline for this study. Dr. Dibello is an employee of GlaxoSmithKline and reports stock holdings. Dr. Van Den Eeden report funding from Takeda not related to the topic of this study. Drs. Aaronson, Li, Weinmann, Ritzwoller, and Richert-Boe have no additional financial disclosures to report. |
| ✯✯ | Funding:This study was supported by a research grant from GlaxoSmithKline. |
Vol 119
P. 70-78 - septembre 2018 Retour au numéro
Article précédent
- Health Education and Symptom Flare Management Using a Video-based m-Health System for Caring Women With IC/BPS
- Ming-Huei Lee, Huei-Ching Wu, Chien-Ming Tseng, Tsung-Liang Ko, Tang-Jun Weng, Yung-Fu Chen
- Analysis of National Trends in Hospital Acquired Conditions Following Major Urologic Surgery Before and After Implementation of the Hospital Acquired Condition Reduction Program
- Tope L. Rude, Nicholas M. Donin, Matthew R. Cohn, William Meeks, Scott Gulig, Samir N. Patel, James S. Wysock, Danil V. Makarov, Marc A. Bjurlin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?